{
  "node_id": "ich-q3a-r2-impurities-new-drug-substances",
  "title": "ICH Q3A(R2): Impurities in New Drug Substances",
  "domain": "Pharmaceuticals & Life Sciences",
  "version": "1.0.0",
  "last_updated": "2026-05-31",
  "bluf": "ICH Q3A(R2) sets reporting, identification, and qualification thresholds for organic impurities in new drug substances based on maximum daily dose…",
  "paywall": {
    "status": "LOCKED",
    "unlock_cost_usd": "0.01",
    "skyfire_id": "41779894-ece2-4163-9761-b3b1b76e19b0"
  },
  "crosswalks": {
    "_available_keys": [
      "eu_ph_eur",
      "us_fda",
      "ich_q3b",
      "ich_q3c",
      "industry_mapping"
    ],
    "_note": "Full crosswalk values included in vault response"
  },
  "primary_citations_count": 5,
  "workflow_steps_count": 8,
  "schema_fields_count": 17,
  "citation_preview": [
    "ICH Harmonised Tripartite Guideline Q3A(R2) Impurities in New Drug Substances, October 2006",
    "European Pharmacopoeia general Control of impurities in substances for pharmaceutical use"
  ]
}